<DOC>
	<DOCNO>NCT00486811</DOCNO>
	<brief_summary>The purpose study evaluate whether tapentadol ( CG5503 ) prolonged-release ( PR ) tablets dose 100-250 mg twice daily provide good pain relief patient moderate severe chronic pain due osteoarthritis knee placebo ( medication without active substance ) . In addition tolerability CG5503 PR assess . One third patient receive CG5503 one third receive placebo . For comparison one third patient receive oxycodone control release ( CR ) dose 20-50 mg twice daily active approve pain medication . Please note tapentadol ER ( Extended Release ) tapentadol PR ( Prolonged Release ) identical use interchangeably . This due United States America European naming convention .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety CG5503 Prolonged Release ( PR ) Subjects With Moderate Severe Chronic Pain Due Osteoarthritis Knee</brief_title>
	<detailed_description>This randomize ( study medication assign patient chance ) , double-blind ( neither patient investigator know patient get study medication , i.e . CG5503 , placebo , oxycodone ) , placebo active control study . The primary objective evaluate efficacy safety orally administer tapentadol ( CG5503 ) prolonged-release ( PR ) dose 100-250 mg ( base ) twice daily patient moderate severe chronic pain osteoarthritis ( OA ) knee . The study consist five period : screening ( assess eligibility ) , washout ( 3-7 day determination baseline pain intensity ) , titration ( dose 3 week optimal individual level ) , maintenance ( investigational drug intake 12 week adjustment allow ) , follow-up ( 2 week end treatment ) . The study hypothesis study drug effective placebo reduce patient ' pain intensity . The secondary objective include collection pharmacokinetic ( related body absorbs , distribute , change excrete drug ) information dose verification . The efficacy objective assess compare baseline pain level pain level maintenance period . This do look patient ' pain diary information ( electronic diary ) .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Patients diagnose osteoarthritis knee base American College Rheumatology ( ACR ) criteria functional capacity class I III ; Patients take analgesic medication least 3 month prior screen dissatisfy current therapy ; Patients require opioid treatment must take daily dos opioid base analgesic , equivalent &lt; 160 mg oral morphine ; Baseline score &gt; =5 11point numeric rating scale , calculated average pain intensity last 3 day prior randomization . History alcohol and/or drug abuse Investigator 's judgment ; Chronic hepatitis B C , HIV , presence active hepatitis B C within past 3 month ; Lifelong history seizure disorder epilepsy ; History malignancy within past 2 year , exception basal cell carcinoma successfully treat ; Uncontrolled hypertension ; Patients severely impair renal function ; Patients moderate severely impaired hepatic function laboratory value reflect inadequate hepatic function , Treatment neuroleptic , monoamine oxidase inhibitor , serotonin norepinephrine reuptake inhibitor ( SNRI ) , tricyclic antidepressant , anticonvulsant , antiparkinsonian drug , treatment analgesic therapy investigational medication rescue medication trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
	<keyword>Pain Assessment</keyword>
	<keyword>CG5503 PR</keyword>
	<keyword>Centrally act analgesic</keyword>
	<keyword>Placebo</keyword>
	<keyword>Oxycodone</keyword>
	<keyword>Chronic Pain due knee Osteoarthritis</keyword>
	<keyword>Tapentadol</keyword>
</DOC>